VHIO SPECIAL SYMPOSIUM:
Towards Predictive Cancer Models
26-27 May 2016
Barcelona – Spain
- Symposium Rationale from your Symposium Co-Chairs
- Symposium Format
- Scientific Program
- Registration & Abstract Submission: Absract Submission now closed
- Dates for the Diary
Symposium Rationale from your Symposium Co-Chairs
In our collective onslaught against cancer the problems that we are all trying to solve are somewhat daunting, yet not insurmountable. While we believe solutions are within reach, they will need to be tackled collectively from different angles, employing diverse approaches, and conquered en force by all oncology professionals who see and understand things differently, from varying viewpoints.
In the current era of precision oncology, advances in translational cancer science and medicine are driven through multidisciplinarity. As we increasingly work in close connectivity whereby researchers and physician-scientists interact together on a daily basis, we have never before been better placed as a community to transform discovery into direct benefits for patients as quickly as possible. Fittingly, our Symposium will be inaugurated by perspectives presented by Josep Tabernero, Director of VHIO, on What Clinicians Expect from a Preclinical Cancer Model.
Conversation surrounding which predictive cancer models outperform others has been widely documented in the literature with each undergoing intense scrutiny. The predictive power of current preclinical models and the reliability of the data reported through recent studies are frequently called into question upon review of false positive results coupled with the compounds that, while showing efficacy in preclinical studies, ultimately fail in early phase trials.
According to a recent study published in eLife*, for example, colleagues from McGill University in Canada analyzed all the published animal studies of sunitinib and found that research reporting little or no anti-cancer effect were not published, leading to anticancer effects of the drug to be overestimated by as much as 45%. Whether this be the case or not, we do know that predicting which drug, or drug combination, will be the most effective based on the genetic makeup of a tumor remains a huge challenge, as does delivering on the promise of precision medicine for an increasing number of patients
We also know that it´s not a question about where to pin the best model medal. Each has its strengths, its limitations. By definition, no predictive model perfectly recapitulates human disease. While competition arguably spurs progress, our energies must focus on the collective end-goal of expanding and potentiating our current anti-cancer weaponry, as opposed to, discussion for discussion´s sake. The performance of a given model is a matter of extensive debate given the large number and range of different models employed in preclinical cancer research. Further, the requirements of any given model for cancer depends on which part of the disease is modeled, e.g. disease initiation, tumor growth, metastasis.
Just some of the must-have conversations during our Symposium will focus on future study design and how best to report, validate and share results so that we can ultimately build on the undeniable progress marked to-date by each and every model explored throughout our two-day symposium. We will be updated on the very latest research evidencing the ´tried, tested and validated´ of a variety of modeling systems and combined approaches across various tumor types as well as cutting-edge data coming from within the ´stable´ of novel contenders — organoids and PDX models. We will also discuss how data from preclinical models can be complementary to tumor genetic testing and thus push the boundaries of sequence-based approaches.
Our focus will center firmly on empowering current predictive cancer models by pooling knowledge, sharing perspectives and moving together to more swiftly, and more cost-effectively advance cancer precision medicine.
We look forward to welcoming you all to a meeting that will represent an important forward step in advancing prediction science against cancer,
Your Symposium Co-Chairs
Joaquín Arribas, Director of Preclinical Research, Vall d«Hebron Institute of Oncology (VHIO)
Laura Soucek, Principal Investigator, Mouse Models of Cancer Therapies Group, Vall d«Hebron Institute of Oncology (VHIO)
*A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib.Henderson VC1, Demo N1, Hakala A1, MacKinnon N1, Federico CA1, Fergusson D2, Kimmelman J1. Elife. 2015 Oct 13;4:e08351
Our forthcoming Vall d´Hebron Institute of Oncology (VHIO) two-day Special Symposium on Towards Predictive Cancer Models, 26 – 27 May, 2016, Barcelona, Spain, has been expertly engineered to bring together an expert panel of internationally acclaimed speakers who will present and debate on and around the five especially selected sessions: 1) Cancer Immunology and Tumor Microenvironment, 2) New Prospectives, 3) Circumventing Therapy Resistance, 4) Redefining the Targets, and 5) New Opportunities from Human Tumor Samples: Explants, Organoids, and PDX.
Interspersed throughout the program we will also learn from, and interact with, our trio of keynote presenters, Lisa Coussens (USA), Scott Lowe (USA), and Mariano Barbacid (Spain), who will deliver the very latest discovery into complex interactions between immune system machinery and the dominant force in multi-drug resistance – the tumor microenvironment, crucial insights into cancer drivers provided by modelling cancer using non-germline GEMMS, as well as evidencing the necessity of modelling K-Ras tumors in mouse models as the test-bed for developing future therapies, respectively.
In addition to the main scientific program, we can also expect to discover yet more relevant and recent advances in predictive cancer science throughout the poster and networking sessions twinned throughout the two lunch breaks. Posters will be divided and displayed across these sessions with their respective author(s) present to discuss their data directly with us all. Following directly after lunch, prior to kicking off the next main symposium session, there will be three invited short talks selected from among the abstracts received.
In recognition of these contributions to our Symposium, prizes sponsored by Nature Reviews Cancer will be awarded to the presenters of the top two posters at the close of the meeting on Friday 27 May.
All registered participants are warmly invited to our Symposium Celebratory Cocktail. Commencing straight after the close of session on Thursday 26 May, we can look forward to our ´mix & mingle´ while enjoying an aperitif complete with traditional culinary delights.
Vall d´Hebron Institute of Oncology (VHIO) Special Symposium:
Towards Predictive Cancer Models
Barcelona, 26 – 27 May, 2016
PLEASE NOTE: our Scientific Program will be regularly updated. Please bookmark this page for all the latest information.
Thursday, May 26th
|8:45 – 9:00||Welcome Address:
Joaquín Arribas, Symposium Co-Chair
Esther Planas, Corporate Director of Finance and Resources, “la Caixa” Foundation (Spain)
Laura Soucek, Symposium Co-Chair
|Jordi Rodón (Spain): What Clinicians Expect from a Preclinical Cancer Model|
|Session I (a): Cancer Immunology and Tumor Microenvironment|
|Keynote I: Lisa Coussens (USA): Immune Reprogramming in Solid Tumors as a Therapeutic Strategy|
|Victor Mulero (Spain): Modeling the Impact of Inflammation in Cancer Progression Using the Zebra Fish|
|Joaquin Arribas (Spain): Modeling Breast Cancer Therapy|
|Session I (b): Cancer Immunology and Tumor Microenvironment|
|Gerard Evan (UK): Building Mouse Cancer Models Using Switchable Mouse Genetics to Model Cancer Evolution and Cancer Therapy|
|Marisol Soengas (Spain): Imaging and Targeting Premetastatic Niches in Melanoma|
|Session II: New Prospectives|
|Josep Villanueva (Spain): Diagnostic and Therapeutic implications of Unconventional Protein Secretion in Cancer|
|Marco Milan (Spain): The Other Side of Genomic Instability in Tumorigenesis: a Fly View|
|Joan Seoane (Spain):Intratumor Heterogeneity and Clonal Evolution in Glioblastoma|
|Lunch & Poster Session I|
|Short talk from posters #1|
|Short talk from posters #2|
|Short talk from posters #3|
|Session III: Circumventing Therapy Resistance|
|Violeta Serra (Spain): Circumventing Resistance to PARP Inhibitors|
|Jos Jonkers (The Netherlands): Genetic Dissection of Breast Cancer, Therapy Response and Resistance in Mouse Models|
|´Mix & Mingle´ Cocktail Reception|
|Speakers & Oral Poster Presenters´ Dinner|
Friday, May 27th
|Session IV: Redefining the Targets|
|Keynote II: Scott Lowe (USA): Tumor Suppressor Networks|
|Louis Chesler (UK): Modeling and Targeting Pediatric Malignancies Using a Gene-Driven in-vivo Approach|
|Laura Soucek (Spain): Drugging the “Undruggable”: Inhibiting Myc to Combat Cancer|
|Maria Dominguez (Spain): A Drug Screen in a Drosophila Tumor Model Identifies Novel Anti-Cancer Drugs Effective in High-Risk Acute Lymphoblastic Leukemia|
|Session V (a): New Opportunities from Human Tumor Samples: Explants, Organoids and PDX|
|Eduard Batlle (Spain): Model Systems to Study Colorectal Cancer Metastasis|
|Héctor G. Palmer (Spain): New Pre-Clinical Models to Study Target-Directed Drugs in Advance Colorectal Cancer|
|Herve Tiriac (USA): Accelerating Therapeutic Discovery with Human Pancreatic Organoids|
|Carlos Caldas (UK): Tumor Explants as a Pre-Clinical Drug Screening Platform in Human Breast Cancer|
|Lunch & Poster Session II|
|Short talk from posters #4|
|Short talk from posters #5|
|Short talk from posters #6|
|Keynote III: Mariano Barbacid (Spain): Modeling Human K-RAS Mutant Tumors in Mice: an Essential Tool for the Development of Future Therapies|
|Session V (b): New Opportunities from Human Tumor Samples: the Strengths of Explants, Organoids and PDX|
|Maurizio Scaltriti (USA): Therapeutic Strategies Tested and Validated in PDXs|
|Silvia Giordano (Italy): PDXs as a Tool to Design New Therapeutic Strategies for Gastric Cancer|
|Co-Chairs Joaquín Arribas & Laura Soucek: Take Home Messages & Close|
Registration & Abstract Submission
Registration covers access to all Scientific Sessions, the Program & Abstract Book, the Symposium ´Mix & Mingle´ Cocktail Reception (immediately following the close of the final session on Thursday 26 May 2016 as of 17:00h), coffee breaks and buffet lunches (poster and networking sessions).
REGISTRATION ONLINE IS NOW CLOSED.
IF YOU HAVE NOT YET REGISTERED AND WISH TO PARTICIPATE, YOU MAY REGISTERONSITE THROUGHOUT THE COURSE OF THE SYMPOSIUM.
|Early registration fees
|Regular registration fees
(incl. PhD Students)
|100 EUR||150 EUR|
|Academic||150 EUR||200 EUR|
|Industry||200 EUR||300 EUR|
PLEASE NOTE: registration does NOT include accommodation. Each participant must organize his/her own accommodation. For information about the official Symposium hotel and alternative accommodation situated close by to the symposium venue see below under ´Accommodation´.
ABSTRACT SUBMISSION IS NOW CLOSED.
Upon review by the Symposium Co-Chairs, abstracts will either be selected as posters or invited short talks scheduled within the main program directly following the two lunch and poster sessions. Topic scope will correspond to the main five symposium session themes.
PLEASE NOTE: Abstracts must not exceed max. 2550 characters (incl. spaces)
Abstract Submission is closed. IMPORTANT: AUTHORS will be notified by email of acceptance as soon as possible as of 02 May 2016.
The best six abstracts will be selected to be presented in oral format; the remaining abstracts will be presented in poster format.
As a reflection of the scientific programme of excellence, Nature Reviews Cancer is sponsor of our two poster prizes – to be announced and awarded by a special guest – to the presenters of the top two posters at the close of the meeting on 27 May.
PLEASE NOTE: the presentation of an abstract, either orally or as a poster, requires the registration of at least one of the authors to attend the Symposium.
PLEASE NOTE: due to an increased number of participants we will now be holding this Symposium in the Auditorium of the Pabellón Docente Building, the Vall d´Hebron University Hospital campus:
Pabellón Docente Auditorium
The Vall d´Hebron University Hospital
Natzaret Street with Arquitectura St.
08035 Barcelona, Spain
Dates for the Diary
|Regular Registration Closes:||23 May 2016|
PLEASE NOTE: registration does NOT include accommodation. Each participant must organize his/her own accommodation directly. For information about the official symposium hotel and alternative accommodation downtown, please click here. Should you have any queries regarding accommodation please contact our officially appointed scientific event logistics company OMNIPREX © INTERNATIONAL GROUP via email:VHIOsymposiumTPCM@omniprex.com.
On behalf of VHIO, the Symposium Co-Chairs gratefully thank the generous support received from the “La Caixa Foundation”:
For all queries concerning registration and/or abstract submission, and recommended options regarding accommodation please contact our officially appointed scientific event logistics company OMNIPREX © INTERNATIONAL GROUP:
Avda. Diagonal, 401 2º piso, 08008 Barcelona
Tel. +34 93 207 0478